drugset
drugset / Trial / NCT05004311

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

NCT05004311 ↗

Phase 1 Completed 16 enrolled Viatris Innovation GmbH
Non-randomizedParallel-groupOpen-labelOther

Summary

To investigate the PK of cenerimod in participants with severe renal impairment as compared to healthy control participants.

Timeline

Start
2021-09-27
Primary completion
2023-07-27
Completion
2023-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenerimod Small molecule 0.5 mg Oral

Indications

impaired renal function disease